REGEMAT 3D Advances Biofabrication with the Development of Next-GenerationBioreactors

Granada, Spain – November 28, 2024 – REGEMAT 3D is proud to announce the ongoing
development of novel bioreactors by its in-house engineering team, reinforcing the
company’s dedication to advancing the next generation of biofabrication technologies for
regenerative medicine and tissue engineering.
These new bioreactors are part of REGEMAT 3D’s robust R&D strategy, aimed at delivering
innovative and customizable tools that enable researchers and clinicians to push the
boundaries of science and clinical applications.
By combining engineering precision with biological insight, REGEMAT 3D continues to
design solutions that support cell growth, tissue remodeling, and complex dynamic culture
conditions — all key factors in creating more realistic and functional tissue models.
Stay tuned for further updates as we continue to innovate and help shape the future of
biofabrication.
For more information, visit www.regemat3d.com